In line with previous observations that blockade of olaparib-upregulated PLK1 improved olaparib’s anticancer efficacy [21], potentiated cytotoxicity by olaparib plus AZD1775 might be, at least partially, due to PLK1 suppression by AZD1775 in GC cells. The gene discussed is PLK1; the disease is gastric cancer.